Biography for Ryan McBride
Ryan McBride is an award-winning journalist who writes about the life sciences industry. Prior to joining FierceMarkets, he was a freelance journalist and served as a correspondent at Xconomy for more than two years. His stories have appeared in The Boston Globe, the Boston Business Journal, The Motley Fool, and many other publications. In recent years, he has also given guest lectures to graduate students at Boston University’s Center for Science & Medical Journalism. Earlier in his career, he held staff reporter positions at Mass High Tech, Providence Business News, and The Westerly Sun. Ryan enjoys spending time with his family and exploring mountains and beaches in New England. Follow Ryan on Twitter at @RyanMFierce or send him e-mail here.
Articles by Ryan McBride
UPDATED: Quintiles adds in-house genomic testing with latest buyout
Quintiles has scooped up a provider of genomic testing and analysis as the global pharma services company beefs up its internal capabilities to support the development of personalized drugs. With the buyout of Expression Analysis, Quintiles builds on a series of acquisitions and alliances that advance the genomics revolution into research labs and clinical trials.
Report sheds light on pharma and CRO trial enrollment woes
A DecisionView study shows that only 6% of drug trials wrap up on time, with 72% of studies missing deadlines by more than a month.
CRO lobby steps up social media outreach on YouTube
Clinical research organizations have grown their share of global clinical research business over the years, and the contract drug developers have found an online platform to carry their message around the world: YouTube.
Big quarterly loss whacks ex-Biogen chief's CMO amid transition
Wait until the second half of the fiscal year was Patheon ($PTI) CEO Jim Mullen's message after the contract drugmaker reported a $20.9 million loss.
Devicemakers eye outsourcing to limit hit from Obama tax
The medical device industry has waged war on a new tax on device makers as part of Obama's healthcare reform, and companies have begun talking up plans to outsource manufacturing work overseas as a result of the tax.
